Quell Therapeutics

Quell Therapeutics

Verified
Developing next generation engineered T-regulatory cell therapies for a range of solid organ transplant and autoimmune conditions

Launch date
Employees
Ownership
Market cap
-
Net debt
-
Firm valuation
$624—936m (Dealroom.co estimates Nov 2021.)
London England (HQ)
  • Edit

Recent News about Quell Therapeutics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.